RENT.COM.AU LIMITED — AGM Information 2008

Mar 18, 2008

Annual General Meeting

==> picture [720 x 129] intentionally omitted <==

----- Start of picture text -----

Product Pipeline
----- End of picture text -----

PRODUCT	RESEARCH	DEVELOPMENT	APPROVAL
VACCINES
Influenza
Hepatitis C
Malaria
HIV
THERAPEUTICS

==> picture [720 x 129] intentionally omitted <==

----- Start of picture text -----

Company Focus
----- End of picture text -----

• VLP vaccine development for key targets

• Hepatitis C, in-house or with partners

• Influenza, in-house or with partners

• Other diseases with partners or with non-dilutional grant support

• Antiviral drug development

– Anti-picornaviral drugs, pending partnerships

• Diagnostics

• Royalties from licensed products: no further activity

==> picture [720 x 129] intentionally omitted <==

----- Start of picture text -----

Virus-like Particle (VLP) Vaccines
----- End of picture text -----

• VLPs have a 20 year history of use in vaccines for Hepatitis B and now human papillomaviruses

• The success of Merck/CSL’s Gardasil vaccine for HPV has increased interest in the area

• Advantages of VLP vaccines:

• accommodate a range of large foreign antigens

• ability to induce both antibody and cellular immune responses

• Global vaccine market expected to top US$23.8 billion by 2012

• Adult vaccines will rise from US$3.7 billion (2005) to US$7.5 billion in 2012 due to increased uptake of influenza and hepatitis vaccines

• The fastest growing segments in the adult vaccines area are influenza vaccines and Hepatitis vaccines

• Flu vaccines are forecast to reach US$4 billion by 2012.

• Normal HBV VLPs (22nm dia.) typically only allow small antigens or parts of antigens to be inserted without disruption of VLP structure

• Novel VLPs derived from duck hepatitis B virus (DHBV) that incorporate 2 separate protein species - small surface protein (S)

• overlapping large surface protein (L)

• DHBV VLPs can contain inserts of >680 amino acids in the second (L) surface protein

• Large size of our VLP (45-60nm dia.) facilitates interaction with dendritic cells, resulting in potent

==> picture [720 x 129] intentionally omitted <==

----- Start of picture text -----

VLP Platform
----- End of picture text -----

• Unique and versatile platform that can deliver a range of vaccine candidates

• Platform validated in small animal studies for a range of vaccine antigens

• Significant improvements to existing VLP technologies:

• The size of the VLPs which allow for the attachment of larger and more complex antigens

• The potency of the resulting vaccine

• No need for an adjuvant leading to reduced cost and risk in

• New flu VLPs based on M2e antigen produced; immunogenicity study in progress

• Establishing stable cGMP co-expression systems for production of DHBV VLPs in mammalian cells and yeast

• Feasibility study on the co-expression of S and flu HA proteins in yeast (Artes Biotech, Germany)

• Co-expression of S and H5 HA-S successful

• HA VLP formation successful

• VLP characterisation and stability studies in progress;

==> picture [720 x 129] intentionally omitted <==

----- Start of picture text -----

R&D Update cont’d
----- End of picture text -----

• Feasibility study on the co-expression of S and HCV E1E2 proteins in mammalian cells (Catalent Pharma Solutions, USA)

• Retrovector production/transductions completed

• Characterization of co-expression in progress

==> picture [720 x 129] intentionally omitted <==

----- Start of picture text -----

Upcoming Milestones
----- End of picture text -----

• Initial development of scalable yeast and mammalian cell-expression systems due for completion by Q2 2008

• Three products to enter further preclinical testing in Q1 and Q2 2008

• Hepatitis C VLP will proceed into further preclinical studies to test for indications of a specific immune response.

• First VLP vaccine targeting ‘flu will proceed into preclinical testing to establish indications of a specific immune response and manufacturing proof-of-capability.

• New VLP vaccine targeting ‘flu will proceed into the first stage of

==> picture [720 x 129] intentionally omitted <==

----- Start of picture text -----

Intellectual Property – DHBV VLPs
----- End of picture text -----

TERRITORY	APPLICATION NO	STATUS
VIRAL VECTOR
International (PCT)	PCT/AU2004/00511	International phase complete
Australia	2004231119	Pending
Europe	04727789.2	Pending
People's Republic of China	200480013729.7	Pending
United States of America	10/553,683	Pending
RECOMBINANT PROTEINS (VIRAL VECTORS II)

RECOMBINANT PROTEINS (VIRAL VECTORS II)

Filed on Aug 07; due to enter

• Picornaviruses involved in many types of pathology

– Hundreds enterovirus and rhinovirus subtypes

• Identification of lead compounds for non-nucleoside RNAdependent RNA polymerase inhibitors

• Amiloride and related molecules

• Novel pharmacology discovered and patented

• Target and mechanism of action identified

• Sequence and structural analysis performed

• Antiviral market set to reach US$20.5B by 2008 – US $9.2B sales in USA by 2008*

• In the US alone picornaviruses account for:

• 34m physician visits pa

• Over US $6b spent on OTC and prescription medicines

• 30% of all school absences; 40% of all lost work time

• Estimated market potential for human rhinovirus treatments is US$400m+

• no

• Currently there is specific antiviral treatment licensed for

==> picture [720 x 129] intentionally omitted <==

----- Start of picture text -----

Intellectual Property - Anti-virals
----- End of picture text -----

TERRITORY	APPLICATION NO	STATUS
ANTI-VIRAL COMPOUNDS
International(PCT)	PCT/AU03/0093	International phase complete
Australia	2003202298	Granted
Canada	2474821	Pending
Europe	3700694.7	Pending
New Zealand	534292	Pending
People's Republic of China	3804954.6	Pending
United States of America	10/503,324	Pending

• Share Price

$0.018

(At 18/03/2008)

• Market Cap $4.6M

(At 18/03/2008)

• Cash (At 31/12/07)

$1.64M

• Shares

255,350,452

• Options (SLTOA)

23,479,265

==> picture [720 x 129] intentionally omitted <==

----- Start of picture text -----

Management
----- End of picture text -----

• Dr Martin Soust

Chief Executive Officer

• A/Prof. David Anderson

Chief Scientific Officer

• Mr Richard Wadley

Chief Financial Officer

• Dr Fan Li

Operations Manager

==> picture [720 x 129] intentionally omitted <==

----- Start of picture text -----

Board
----- End of picture text -----

• Mr Robin Beaumont

Chairman

• Mr R Shane Allan

• Dr Ian Cooke

• Mr George Weber

• Dr Martin Soust

Non-Executive Director Non-Executive Director Non-Executive Director Executive Director